Keyword Index for Volume 93 by unknown




















advanced breast cancer 515
advanced head and neck cancer
884
advanced pancreatic cancer 185



























apoptosis 1, 70, 208, 233, 973,
1157, 1356






















brain tumours 152, 781
BRCA1 287
BRCA2 287
breast cancer 167, 287, 293, 364,
392, 406, 520, 590, 627, 694,
699, 793, 817, 924, 973, 1005,
1062, 1128, 1152, 1168, 1215,
1295, 1372
breast cancer mortality 392
breast cancer stage 1046
breast carcinoma 1046
breast neoplasm 582, 1122









calcium sensing receptor 1364
calprotectin 639
cancer cachexia 425
cancer of the small intestine 807
cancer of the testis 909
cancer predisposition 260
cancer registries 159, 372
cancer vaccine 1250
capecitabine 510, 1117










CD4 and CD8 lymphocytes 435
cell cycle 939




chemotherapy 29, 54, 224, 233,




















circulating endothelial cells 793
cisplatin 178, 529, 678, 763,







cohort studies 804, 807, 1053,
1310




colorectal cancer 1, 399, 510,













































ductal carcinoma in situ 1122
dysadherin 1382
early breast cancer 1319
early-onset breast cancer 260
E-cadherin 1364, 1382
ectodomain shedding 1267
ED1 and ED2 macrophages
435







endometrial cancer 999, 1062
endostatin 1024













ETA and ETB receptors
distribution 98








British Journal of Cancer (2005) 93, 1407–1410

























free fatty acids 639
galectin-3 1175
gastric cancer 688, 986, 1395
gastrocnemius muscle 774
gefitinib 23, 915, 1334





gene expression 1182, 1277






















































human breast cancer 946
human papillomavirus 116, 946
hyaluronidase 81
hypermethylation 1395














immunotherapy 458, 670, 749

















irinotecan 763, 1106, 1230, 1341
isoflavones 15
Japan Collaborative Cohort





















liquid-based cytology 242, 575
liver 890
local neoplasm recurrence 1122











lung cancer 652, 719, 825, 905,
1329












































metastatic gastric cancer 190










protein 6 (MCM6) 939















multidrug resistance 46, 89
multidrug resistance protein
216





n-3 fatty acids 639
NADPH cytochrome P450
reductase 89
















nonmelanoma skin cancer 597
non-small-cell lung cancer 23,
29, 450, 453, 850, 977, 1098,
1106, 1202, 1334, 1341
Keyword index
1408




NSCLC 763, 770, 1157
NU7026 1011




obesity 582, 1062, 1310
oesophageal cancer 107, 1112
oestrogen 392, 859
oestrogen plus progestin 392
oestrogen receptor 1046












ovarian cancer 60, 973
ovarian carcinoma 709
ovarian neoplasms 647
ovarian surface epithelium 116
overall survival 453
oxaliplatin 29, 190, 993, 1230
oxidative stress 331, 757
p16 933
p53 242, 355









pancreatic cancer 35, 195, 441,
740, 1062



















phase I clinical trial 876
phase I study 1222















primary breast cancer 552
primary chemotherapy 406
primary health care 399
probability 1244
prognosis 7, 124, 137, 152, 450,






proliferation 208, 338, 515,
939
prospective studies 986, 1310
prostate cancer 478, 493, 633,










psychological well being 1092
PTEN 124
public health 862
quality of life 200, 1202, 1236






randomised 279, 757, 862














referral and consultation 399
regional variation 520
regions of imbalance 1191
regulatory agencies 504
relative risk of death 571
REMARK 387

















screening 376, 862, 1077
season of diagnosis 571






























squamous cell head and neck
cancer 279





surrogate end point 195
surrogate markers 1215



















































tumour marker 195, 387
tumour oxygenation 224
















British Journal of Cancer (2005) 93(12), 1407–1410 & 2005 Cancer Research UKvariability 208

















British Journal of Cancer (2005) 93(12), 1407–1410 & 2005 Cancer Research UK